HFE genotype influences erythropoiesis support requirement in hemodialysis patients: A prospective study

American Journal of Nephrology

Volumn 28, Issue 2, 2008, Pages 311-316

  Valenti, Luca ^a   Valenti, Giovanni ^a   Como, Giovanna ^a   Santorelli, Gennaro ^a   Dongiovanni, Paola ^a   Rametta, Raffaela ^a   Fracanzani, Anna Ludovica ^a   Tavazzi, Dario ^a   Messa, Pier Giorgio ^a   Fargion, Silvia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Chronic dialysis; Erythropoietin; Genetics; Hemodialysis; Hepcidin; HFE protein; Iron

Indexed keywords

FERRIC GLUCONATE; HEMOGLOBIN; HFE PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE COURSE; ERYTHROPOIESIS; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERTENSION; IRON ABSORPTION; IRON STORAGE; ITALY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESTRICTION MAPPING; SURVIVAL RATE; TREATMENT DURATION; TREATMENT INDICATION;

AGED; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; ITALY; KIDNEY FAILURE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 38349079092     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111387     Document Type: Article

References (26)

1. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2):ii1-ii47.
2. Kletzmayr J, Horl WH: Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 2002;17(suppl 2):25-29.
3. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3070-3080.
4. Torti FM, Torti SV: Regulation of ferritin genes and protein. Blood 2002;99:3505-3516.
5. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002;13:734-744.
6. Roest M, van der Schouw YT, de Valk B, Marx JJ, Tempelman MJ, de Groot PG, Sixma JJ, Banga JD: Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 1999;100:1268-1273.
7. Zacharski LR, Chow B, Lavori PW, Howes PS, Bell MR, DiTommaso MA, Carnegie NM, Bech F, Amidi M, Muluk S: The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J 2000;139:337-345.
8. Wolff B, Volzke H, Ludemann J, Robinson D, Vogelgesang D, Staudt A, Kessler C, Dahm JB, John U, Felix SB: Association between high serum ferritin levels and carotid atherosclerosis in the study of health in Pomerania (SHIP). Stroke 2004;35:453-457.
9. Michelis R, Gery R, Sela S, Shurtz-Swirski R, Grinberg N, Snitkovski T, Shasha SM, Kristal B: Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003;18:924-930.
10. Miyashita K, Tojo A, Kimura K, Goto A, Omata M, Nishiyama K, Fujita T: Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res 2004;27:79-84.
11. Camaschella C: Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 2005;106:3710-3717.
12. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P: Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769-1778.
13. Gehrke SG, Herrmann T, Kulaksiz H, Merle U, Bents K, Kaiser I, Riedel HD, Stremmel W: Iron stores modulate hepatic hepcidin expression by an HFE-independent pathway. Digestion 2005;72:25-32.
14. Valenti L, Valenti G, Como G, Burdick L, Santorelli G, Dongiovanni P, Rametta R, Bamonti F, Novembrino C, Fracanzani AL, Messa PG, Fargion S: HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. Am J Nephrol 2007;27:101-107.
15. Pericole FV, Alves MA, Saad ST, Costa FF: Hemochromatosis (HFE) gene mutations in Brazilian chronic hemodialysis patients. Braz J Med Biol Res 2005;38:1321-1324.
16. Canavese C, Bergamo D, Barbieri S, Timbaldi M, Thea A, Martina G, Damiani D, Fenoglio R, Donati-Marella B, Priolo G: Clinical relevance of hemochromatosis-related HFE C282Y/H63D gene mutations in patients on chronic dialysis. Clin Nephrol 2002;58:438-444.
17. Valenti L, Conte D, Piperno A, Dongiovanni P, Fracanzani AL, Fraquelli M, Vergani A, Gianni C, Carmagnola L, Fargion S: The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J Med Genet 2004;41:946-950.
18. Girndt M, Stenvinkel P, Ulrich C, Axelsson J, Nordfors L, Barany P, Carrero JJ, Heine GH, Kaul H, Kohler H: Influence of cytokine gene polymorphisms on erythropoetin dose requirements in chronic haemodialysis patients. Nephrol Dial Transplant 2007;[Epub ahead of print].
19. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;15:1623-1632.
20. Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-388.
21. Tutal E, Sezer S, Afsar B, Arat Z, Ozdemir FN, Haberal M: Additional effect of hyperparathyroidism on inflammatory status and rHuEPO requirements in hemodialysis patients. Transplant Proc 2006;38:2807-2812.
22. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191.
23. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL: Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004;38:1090-1094.
24. Seifert A, von Herrath D, Schaefer K: Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 1987;65:1015-1024.
25. Jean G, Charra B, Chazot C, Vanel T, Terrat JC, Hurot JM, Laurent G: Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias. Nephron 2002;91:399-405.
26. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY: Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007;117:1933-1939.